This is a preview of subscription content, log in via an institution to check access.
REFERENCE
Pompen M, Novak A, Gok M, Gyldmark M, Postmus P, Afram C.Pharmacoeconomic analysis shows that erlotinib is cost-saving versus docetaxel, and cost-effective versus best supportive care in NSCLC. Journal of Thoracic Oncology 2 (Suppl.): 433, No. 8, Aug 2007
Orlewska E, Szczêsna A, Szkultecka-Dêbek M.Budget impact analysis of erlotinib in the treatment of advanced non-small-cell lung cancer in Poland. Journal of Thoracic Oncology 2 (Suppl.): 742, No. 8, Aug 2007
Melosky BL, Taylor SC, Peacock SJ, Johnston K, van der Hoek K.Third-line erlotinib therapy versus best supportive care for advanced non-small cell lung cancer in British Columbia, Canada. Is it cost effective? Journal of Thoracic Oncology 2 (Suppl.): 463-464, No. 8, Aug 2007
Rights and permissions
About this article
Cite this article
Erlotinib seals the deal in NSCLC treatment. Pharmacoecon. Outcomes News 539, 3–4 (2007). https://doi.org/10.2165/00151234-200705390-00004
Published:
Issue Date:
DOI: https://doi.org/10.2165/00151234-200705390-00004